1. Home
  2. GLUE

as of 11-28-2025 12:41pm EST

$16.23
+$0.23
+1.44%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Chart Type:
Time Range:
Founded: 2019 Country:
United States
United States
Employees: N/A City: BOSTON
Market Cap: 308.8M IPO Year: 2021
Target Price: $15.00 AVG Volume (30 days): 980.7K
Analyst Decision: Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: 0.25 EPS Growth: N/A
52 Week Low/High: $3.50 - $16.66 Next Earning Date: 11-06-2025
Revenue: $181,538,000 Revenue Growth: 1112.27%
Revenue Growth (this year): 66.94% Revenue Growth (next year): -59.36%

AI-Powered GLUE Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 70.55%
70.55%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Latest Monte Rosa Therapeutics Inc. News

GLUE Breaking Stock News: Dive into GLUE Ticker-Specific Updates for Smart Investing

All GLUE News

Share on Social Networks: